ClinicalTrials.gg
CompletedNCT00706654ASPIREUpdated Jun 4, 2026Results posted

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

A Phase 3 interventional study of Aripiprazole depot 300 or 400 mg and Aripiprazole 10-30 mg orally in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 98 sites in 15 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
937
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
4th of 125
937 · median 130
Started
2008
with 7 others
Phase 3
34 of 126
1 open now
Registered
51st of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 4th largest by enrollment of the 125 interventional ones that give a count, is one of 8 that started in 2008, is one of 34 in phase 3, and was the 51st registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia

The trial is designed into three treatment phases. Phase 1 is designed to allow for a subject to be converted from the current anti-psychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2 the subject will be stabilized on oral non-generic aripiprazole monotherapy. Once the subject is stabilized in Phase 2 (oral stabilization phase from minimum 8 weeks to maximum 28 weeks), they are eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. During Phase 3, the subject will be assessed for exacerbation of psychotic symptoms and impending relapse for up to 38 weeks.

Read the detailed description

This will be a randomized, double-blind, active-controlled study consisting of a screening phase and 3 treatment phases. Eligibility will be determined during a screening phase of 2 to 42 days. Subjects currently receiving oral treatment with an anti-psychotic other than non-generic aripiprazole will enter Phase 1, and subjects with a lapse in aripiprazole or other anti-psychotic treatment at the time of study entry ("lapse" defined as > 3 consecutive days without medication) will enter directly into Phase 2.

During Phase 1 (oral conversion), subjects will be cross-titrated during weekly visits from other anti-psychotics to oral non-generic aripiprazole monotherapy over a minimum of 4 weeks and a maximum of 6 weeks. During Phase 2 (that will be a minimum of 8 weeks and a maximum of 28 weeks in duration), subjects will be assessed bi-weekly and stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily. After stability criteria are met at Phase 2, subjects are eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. Subjects will be randomized with a 2:2:1 (aripiprazole IM depot 300-400 mg monthly, oral aripiprazole 10-30 mg daily, aripiprazole IM depot 25-50 mg monthly). During Phase 3 subjects will be assessed for impending relapse/exacerbation of psychotic symptoms. If a subject is identified with impending relapse/exacerbation of psychotic symptoms, they will be withdrawn from the trial and given the opportunity to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549). Alternatively, any subject that discontinues in Phase 3 (up to and including Week 38) will have the option to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549).

The enrollment figure includes re-screened patients.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Aripiprazole
  • Intramuscular (IM) depot
  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are able to provide written and/or consent obtained from a legally acceptable representative (as required by Institutional Review Board/Independent Ethics Committee [IRB/IEC]), prior to the initiation of any protocol-required procedures.
  • Male and female subjects 18 to 60 years of age, inclusive, at time of informed consent.
  • Subjects with a current diagnosis of schizophrenia as defined by , version 4, Text Revision (DSM-IV-TR) criteria and a history of the illness for at least 3 years prior to screening.
  • Subjects who, in the investigator's judgment, require chronic treatment with an anti-psychotic medication.
  • Subjects able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, discontinuation of prohibited concomitant medications, who can read and understand the written word in order to complete patient-reported outcome measures, and who can be reliably rated on assessment scales.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic, or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Subjects with schizophrenia that are considered resistant/ to antipsychotic treatment by history or response only to clozapine.
  • Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's judgment.
  • Subjects who currently meet DSM-IV-TR criteria for substance dependence; including alcohol and benzodiazepines, but excluding caffeine and nicotine, or 2 positive drug screens for cocaine.
  • Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones, or to anti-psychotic agents, including aripiprazole.
  • Subjects with a history of neuroleptic malignant syndrome or tardive dyskinesia at screening.
  • Subjects with uncontrolled thyroid function abnormalities.
  • Subjects with a history of seizures, neuroleptic malignant syndrome, clinically significant tardive dyskinesia, or other medical condition that would expose the subject to undue risk or interfere with study assessments.
  • Subjects who are involuntarily incarcerated.
  • Subjects who have undergone electroconvulsive therapy within 180 days of entry into Phase 2.
  • Subjects who have used an agent within 30 days of screening; and prior participation in a clinical study with aripiprazole IM depot.
  • Subjects with clinically significant abnormalities in laboratory test results, vital signs, or results.
  • Subjects hospitalized for more than 30 days in the 90 days prior to Phase 1 (or Phase 2 for subjects bypassing Phase 1).
  • Subjects requiring more than 1 benzodiazepine beyond screening (eg, lorazepam and oxazepam).
  • Subjects who fail to wash-out from prohibited concomitant medications, including the use of CYP2D6 or inhibitors or CYP3A4 inducers, antipsychotics, antidepressants (including monoamine oxidase inhibitors [MAOI]), and mood stabilizers, during screening and Phase 1.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
937 participants (actual)

Study arms

  • Experimental
    Aripiprazole depot 300 or 400 mg

    Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.

    Drug: Aripiprazole depot 300 or 400 mg · Drug: Placebo tablets

  • Active comparator
    Aripiprazole 10-30 mg orally

    Patients received aripiprazole 10-30 mg orally daily for 38 weeks.

    Drug: Aripiprazole 10-30 mg orally · Drug: Placebo depot

  • Experimental
    Aripiprazole depot 25 or 50 mg

    Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.

    Drug: Aripiprazole depot 25 or 50 mg · Drug: Placebo tablets

Interventions

  • DrugAripiprazoleStudies of AripiprazoleAripiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.

    Also known as: Abilify

  • DrugAripiprazoleStudies of AripiprazoleAripiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.

    Also known as: Abilify

  • DrugAripiprazoleStudies of AripiprazoleAripiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.

    Also known as: Abilify

  • DrugPlacebo depot

    Placebo depot was supplied in lyophilized vials.

  • DrugPlacebo tablets

    Placebo tablets were identical in appearance to the aripiprazole tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26

    A patient had exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score \> 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score \> 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Time to Exacerbation of Psychotic Symptoms/Impending Relapse

    Time frame: Baseline to the end of the study (Week 38)

  2. Percentage of Responders up to Week 38

    A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.

    Time frame: Baseline to the end of the study (Week 38)

  3. Percentage of Patients Achieving Remission

    A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).

    Time frame: Baseline to the end of the study (Week 38)

07

Results

Posted Aug 14, 2013

Participant flow

Conversion Phase
Participant flow — Conversion Phase
MilestoneAll PatientsAripiprazole Depot 300 or 400 mgAripiprazole 10-30 mg OrallyAripiprazole Depot 25 or 50 mg
Started709000
Completed614000
Not completed95000
Withdrew: Lost to follow-up4000
Withdrew: Sponsor discontinued trial8000
Withdrew: Met withdrawal criteria2000
Withdrew: Withdrawn by investigator14000
Withdrew: Withdrew consent38000
Withdrew: Adverse event18000
Withdrew: Lack of efficacy with adverse event9000
Withdrew: Lack of efficacy without adverse event2000
Oral Stabilization Phase
Participant flow — Oral Stabilization Phase
MilestoneAll PatientsAripiprazole Depot 300 or 400 mgAripiprazole 10-30 mg OrallyAripiprazole Depot 25 or 50 mg
Started842000
Completed662000
Not completed180000
Withdrew: Lost to follow-up17000
Withdrew: Sponsor discontinue trial19000
Withdrew: Met withdrawal criteria15000
Withdrew: Withdrawn by investigator21000
Withdrew: Withdrew consent55000
Withdrew: Protocol deviation2000
Withdrew: Adverse event21000
Withdrew: Lack of efficacy with adverse event20000
Withdrew: Lack of efficacy without adverse event10000
Depot Maintenance Phase
Participant flow — Depot Maintenance Phase
MilestoneAll PatientsAripiprazole Depot 300 or 400 mgAripiprazole 10-30 mg OrallyAripiprazole Depot 25 or 50 mg
Started0265266131
Completed019617861
Not completed0698870
Withdrew: Lost to follow-up04106
Withdrew: Met withdrawal criteria0465
Withdrew: Withdrawn by investigator08128
Withdrew: Withdrew consent0212914
Withdrew: Protocol deviation0231
Withdrew: Adverse event without impending relapse0877
Withdrew: Impending relapse with adverse event0131217
Withdrew: Impending relapse without adverse event09912

Outcome measures

PrimaryPercentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26

A patient had exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score \> 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score \> 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.

Time frame:
Baseline to Week 26
Reported as:
Number · Percentage of patients
Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26
Percentage of patientsAripiprazole Depot 300 or 400 mg - Depot Maintenance PhaseAripiprazole 10-30 mg Orally - Depot Maintenance PhaseAripiprazole Depot 25 or 50 mg - Depot Maintenance Phase
Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 267.12 (1.62 to —)7.76 (1.72 to —)21.80 (3.97 to —)
Statistical analysis
  • Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase vs Aripiprazole 10-30 mg Orally - Depot Maintenance Phase · z-statistics · p = 0.7871 · Mean difference (final values): -0.64 · 95% CI -5.26 to 3.99The 95% CI of the difference in proportions of subjects with impending relapse events between aripiprazole IM depot 300 or 400 mg mg and oral aripiprazole were provided using the pooled SE with assumption of normality of the estimated difference.
  • Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase vs Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase · z-statistics · p = 0.0006 (Once non-inferiority was declared, superiority of depot 300/400 mg over depot 25/50 mg was tested by the difference between the proportion of subjects experiencing impending relapse by the end of Week 26 (2-sided 0.05 significance level z-statistic).) · Mean difference (final values): -14.68 · 95% CI -23.09 to -6.27The same method was used to compare IM depot 300 or 400 mg with IM depot 25 or 50 mg in the estimated proportion of subjects with impending relapse.
SecondaryTime to Exacerbation of Psychotic Symptoms/Impending Relapse
Time frame:
Baseline to the end of the study (Week 38)
Reported as:
Median · Days
Time to Exacerbation of Psychotic Symptoms/Impending Relapse
DaysAripiprazole Depot 300 or 400 mg - Depot Maintenance PhaseAripiprazole 10-30 mg Orally - Depot Maintenance PhaseAripiprazole Depot 25 or 50 mg - Depot Maintenance Phase
Time to Exacerbation of Psychotic Symptoms/Impending RelapseNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Responders up to Week 38

A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.

Time frame:
Baseline to the end of the study (Week 38)
Reported as:
Number · Percentage of patients
Percentage of Responders up to Week 38
Percentage of patientsAripiprazole Depot 300 or 400 mg - Depot Maintenance PhaseAripiprazole 10-30 mg Orally - Depot Maintenance PhaseAripiprazole Depot 25 or 50 mg - Depot Maintenance Phase
Percentage of Responders up to Week 3889.889.475.2
Statistical analysis
  • Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase vs Aripiprazole 10-30 mg Orally - Depot Maintenance Phase · z-statistics · p = 0.8750
  • Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase vs Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase · z-statistics · p = 0.0001
SecondaryPercentage of Patients Achieving Remission

A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).

Time frame:
Baseline to the end of the study (Week 38)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Remission
Percentage of patientsAripiprazole Depot 300 or 400 mg - Depot Maintenance PhaseAripiprazole 10-30 mg Orally - Depot Maintenance PhaseAripiprazole Depot 25 or 50 mg - Depot Maintenance Phase
Percentage of Patients Achieving Remission48.853.259.7
Statistical analysis
  • Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase vs Aripiprazole 10-30 mg Orally - Depot Maintenance Phase · z-statistics · p = 0.3700
  • Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase vs Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase · z-statistics · p = 0.1097

Adverse events

Collected over Adverse events were reported from the time of the signing of informed consent until the end of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Patients - Conversion Phase—21/709 (3%)140/709 (19.7%)
All Patients - Oral Stabilization Phase—39/842 (4.6%)177/842 (21%)
Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase—15/265 (5.7%)161/265 (60.8%)
Aripiprazole 10-30 mg Orally - Depot Maintenance Phase—15/266 (5.6%)142/266 (53.4%)
Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase—11/131 (8.4%)74/131 (56.5%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventAll Patients - Conversion PhaseAll Patients - Oral Stabilization PhaseAripiprazole Depot 300 or 400 mg - Depot Maintenance PhaseAripiprazole 10-30 mg Orally - Depot Maintenance PhaseAripiprazole Depot 25 or 50 mg - Depot Maintenance Phase
Psychotic disorderPsychiatric disorders8/70915/8424/2652/2664/131
SchizophreniaPsychiatric disorders3/7099/8425/2652/2663/131
Suicidal ideationPsychiatric disorders2/7094/8421/2650/2661/131
SepsisInfections and infestations0/7090/8420/2650/2661/131
ConvulsionNervous system disorders0/7090/8420/2650/2661/131
Neuroleptic malignant syndromeNervous system disorders0/7090/8420/2650/2661/131
Completed suicidePsychiatric disorders0/7090/8420/2650/2661/131
Organising pneumoniaRespiratory, thoracic and mediastinal disorders0/7090/8420/2650/2661/131
Schizophrenia, paranoid typePsychiatric disorders0/7091/8420/2652/2660/131
AgitationPsychiatric disorders0/7091/8421/2650/2660/131
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAll Patients - Conversion PhaseAll Patients - Oral Stabilization PhaseAripiprazole Depot 300 or 400 mg - Depot Maintenance PhaseAripiprazole 10-30 mg Orally - Depot Maintenance PhaseAripiprazole Depot 25 or 50 mg - Depot Maintenance Phase
InsomniaPsychiatric disorders78/70987/84231/26537/26618/131
Weight increasedInvestigations5/70923/84224/26535/2667/131
Back painMusculoskeletal and connective tissue disorders1/70914/84210/26514/26615/131
HeadacheNervous system disorders39/70944/84226/26530/2667/131
AkathisiaNervous system disorders36/70963/84228/26518/26611/131
Weight decreasedInvestigations10/70925/84226/26516/26612/131
NasopharyngitisInfections and infestations17/70918/84221/26525/2669/131
AnxietyPsychiatric disorders28/70935/84219/26513/26610/131
Injection site painGeneral disorders0/7091/84220/2656/2661/131
Upper respiratory tract infectionInfections and infestations14/70912/84218/26511/2665/131

Baseline characteristics

Baseline measures are based on the participants from the Depot Maintenance Phase.

Age, Continuous
Age, Continuous(years)Aripiprazole Depot 300 or 400 mg - Depot Maintenance PhaseAripiprazole 10-30 mg Orally - Depot Maintenance PhaseAripiprazole Depot 25 or 50 mg - Depot Maintenance PhaseTotal
Mean41.7 ± 10.441.2 ± 10.840.2 ± 9.640.7 ± 10.4
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Aripiprazole Depot 300 or 400 mg - Depot Maintenance PhaseAripiprazole 10-30 mg Orally - Depot Maintenance PhaseAripiprazole Depot 25 or 50 mg - Depot Maintenance PhaseTotal
Female1059853256
Male16016878406
08

Study locations

98 sites
  • Cerritos, California 90703, United States
  • Escondido, California 92025, United States
  • Garden Grove, California 92845, United States
  • Oceanside, California 92056, United States
  • Orange, California 92868-3298, United States
  • Orange, California 92868, United States
  • Pasadena, California 91106, United States
  • Pico Rivera, California 90660, United States
  • San Diego, California 92102, United States
  • San Diego, California 92103-8620, United States
  • San Diego, California 92123, United States
  • Torrance, California 90502, United States
  • Washington D.C., District of Columbia 20016, United States
  • Gainesville, Florida 32608, United States
  • Kissimmee, Florida 34741, United States
  • Plantation, Florida 33317, United States
  • Tampa, Florida 33613, United States
  • Chicago, Illinois 60612, United States
  • Oak Brook, Illinois 60523, United States
  • Shreveport, Louisiana 71104, United States
  • Towson, Maryland 21286, United States
  • Kansas City, Missouri 64108, United States
  • Buffalo, New York 14213, United States
  • New York, New York 10003, United States
  • New York, New York 10035, United States
  • Rochester, New York 14624, United States
  • Hickory, North Carolina 28601, United States
  • South Carolina, North Carolina 29425, United States
  • Garfield Heights, Ohio 44125, United States
  • Toledo, Ohio 43609, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Charleston, South Carolina 29401, United States
  • Charleston, South Carolina 29407, United States
  • Johnson City, Tennessee 37614-1707, United States
  • Nashville, Tennessee 37212, United States
  • Arlington, Texas 76011, United States
  • Austin, Texas 78756, United States
  • Richmond, Virginia 23230, United States
  • Milwaukee, Wisconsin 53226, United States
  • Innsbruck, A-6020, Austria
  • Bruges, 8200, Belgium
  • Burgas, 8000, Bulgaria
  • Pazardzhik, 4400, Bulgaria
  • Pleven, 5800, Bulgaria
  • Plovdiv, 4000, Bulgaria
  • Sofia, 1113, Bulgaria
  • Sofia, 1431, Bulgaria
  • Sofia, 1632, Bulgaria
  • Varna, 9000, Bulgaria
  • Santiago, 7500710, Chile
  • Santiago, 7510041, Chile
  • Santiago, 7510186, Chile
  • Santiago, 8053095, Chile
  • Santiago, 8330838, Chile
  • Santiago, 8900085, Chile
  • Temuco, 4781151, Chile
  • Valdivia, 5090145, Chile
  • Zagreb, 10 090, Croatia
  • Zagreb, 10000, Croatia
  • Jämejala, Viljandimaa 71024, Estonia
  • Meegomäe, 65526, Estonia
  • Tallinn, 10613, Estonia
  • Tallinn, 13419, Estonia
  • Tartu, 50406, Estonia
  • Tartu, 50417, Estonia
  • Bully-les-Mines, 62160, France
  • Élancourt, 78990, France
  • Rennes, 35703, France
  • Saint-Nazaire, 44606, France
  • Baja, 6500, Hungary
  • Balassagyarmat, 2660, Hungary
  • Cegléd, 2700, Hungary
  • Győőor, 9024, Hungary
  • Milan, 20142, Italy
  • Milan, 20157, Italy
  • Pisa, 56126, Italy
  • Bełchatów, 97-400, Poland
  • Bialystok, 15-879, Poland
  • Bydgoszcz, 85-096, Poland
  • Choroszcz, 16-070, Poland
  • Krakow, 31-501, Poland
  • Leszno, 64-100, Poland
  • Pruszków, 05-802, Poland
  • Sosnowiec, 41-200, Poland
  • Wroclaw, 50-227, Poland
  • San Juan, 00918, Puerto Rico
  • Pretoria, Gauteng 0001, South Africa
  • Cape Town, Western Province 7530, South Africa
  • Busan, 614-735, South Korea
  • Daejeon, 301-721, South Korea
  • Gwangju, 501-757, South Korea
  • Incheon, 400-711, South Korea
  • Seoul, 110-744, South Korea
  • Seoul, 137-701, South Korea
  • Seoul, 150-950, South Korea
  • Muang, Chiangmai 50100, Thailand
  • Muang, Chiangmai 50200, Thailand
  • Bangkok, 10330, Thailand
09

References and documents

Publications

  • Kane JM, Sanchez R, Baker RA, Eramo A, Peters-Strickland T, Perry PP, Johnson BR, Tsai LF, Carson WH, McQuade RD, Fleischhacker WW. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clin Schizophr Relat Psychoses. 2015 Summer;9(2):79-87. Epub 2015 Feb 24. PubMed 25711509 ↗
  • Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014 Aug;205(2):135-44. doi: 10.1192/bjp.bp.113.134213. Epub 2014 Jun 12. PubMed 24925984 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Aug 2012, 47 months.

Results were first posted in Aug 2013, 1 year after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 47 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2008
First posted
Jun 27, 2008
StartActual
Sep 1, 2008
Primary completionActual
Aug 1, 2012
CompletionActual
Aug 1, 2012
Results first posted
Aug 14, 2013
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00706654
Responsible party
Sponsor
First posted
Jun 27, 2008
Start date
Sep 1, 2008
Primary completion
Aug 1, 2012
Completion
Aug 1, 2012
Results posted
Aug 14, 2013
Last update
Jun 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion